Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Q32 Bio (QTTB)
NASDAQ:QTTB
Holding QTTB?
Track your performance easily
QTTB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.67 - $53.79
Previous Close$3.7
Volume1.13M
Average Volume (3M)226.34K
Market Cap
$45.07M
Enterprise Value-$25.61M
Total Cash (Recent Filing)$89.08M
Total Debt (Recent Filing)$18.40M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 07, 2024EPS Estimate
-$1.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.21
Shares Outstanding12,180,701
10 Day Avg. Volume891,072
30 Day Avg. Volume226,345
Standard Deviation0.26
R-Squared0.00843
Alpha-0.00288
Financial Highlights & Ratios
Price to Book (P/B)2.47
Price to Sales (P/S)38.99
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.94
Enterprise Value/Gross Profit-22.16
Enterprise Value/Ebitda0.54
Forecast
1Y Price Target
$18.17Price Target Upside419.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Q32 Bio News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsQ32 Bio's lead clinical programs bempikibart and ADX-097 are in several ongoing clinical trials that provide multiple opportunities for potential significant share appreciation.
Mechanism Of ActionADX-097 tissue-targeted complement mechanism has the potential to address complement dysfunction in multiple indications.
Product DevelopmentQTTB plans to use capital to fund an expansion trial for alopecia areata, indicating a continued focus on potential areas of success.
Bears Say
Drug DevelopmentDisappointing results for lead asset bempikibart from the Phase 2a SIGNAL-AD and SIGNAL-AA studies have led to a downgrade of QTTB's stock rating.
Financial Model ImpactThe failure of bempikibart to achieve the primary endpoint in the SIGNAL-AD study has resulted in the removal of value for atopic dermatitis from the company's model.
Study Conduct IssuesStudy conduct issues and early treatment discontinuations may confound the interpretation of the efficacy signal for alopecia areata, necessitating further evaluation.
---
Ownership Overview
0.59% Insiders
8.25% Mutual Funds
59.32% Other Institutional Investors
26.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
QTTB FAQ
What was Q32 Bio’s price range in the past 12 months?
Q32 Bio lowest stock price was $3.67 and its highest was $53.79 in the past 12 months.
What is Q32 Bio’s market cap?
Currently, no data Available
When is Q32 Bio’s upcoming earnings report date?
Q32 Bio’s upcoming earnings report date is Nov 07, 2024 which is 45 days ago.
How were Q32 Bio’s earnings last quarter?
Q32 Bio released its earnings results on Aug 08, 2024. The company reported -$1.42 earnings per share for the quarter, missing the consensus estimate of -$0.997 by -$0.423.
Is Q32 Bio overvalued?
According to Wall Street analysts Q32 Bio’s price is currently Undervalued.
Does Q32 Bio pay dividends?
Q32 Bio does not currently pay dividends.
What is Q32 Bio’s EPS estimate?
Q32 Bio’s EPS estimate is -$1.38.
How many shares outstanding does Q32 Bio have?
Q32 Bio has 12,180,701 shares outstanding.
What happened to Q32 Bio’s price movement after its last earnings report?
Q32 Bio reported an EPS of -$1.42 in its last earnings report, missing expectations of -$0.997. Following the earnings report the stock price went down -1.125%.
Which hedge fund is a major shareholder of Q32 Bio?
Among the largest hedge funds holding Q32 Bio’s share is Woodline Partners LP. It holds Q32 Bio’s shares valued at 5M.
---
Q32 Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.17 (419.14% Upside)
$18.17 (419.14% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 84.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.09%
12-Months-Change
Fundamentals
Return on Equity
-93.26%
Trailing 12-Months
Asset Growth
-25.36%
Trailing 12-Months
Company Description
Q32 Bio
Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.
---
QTTB Stock 12 Month Forecast
Average Price Target
$18.17
▲(419.14% Upside)
Technical Analysis
Arcutis Biotherapeutics
―
Context Therapeutics
―
Foghorn Therapeutics
―
Kala Pharmaceuticals
―
Best Analysts Covering QTTB
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-75.35%
reiterated a buy rating 11 days ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -75.35% per trade.
---